Research Highlights

doi:10.1038/nindia.2012.20 Published online 15 February 2012

Flavone for prostate cancer

Researchers have identified the proven antitumor agent P276-00 — a flavone that inhibits cyclin-dependent kinases — as a suitable chemotherapy agent in prostate cancer.

P276-00 inhibits activation of hypoxia-inducible factor-1 (HIF-1). Over expression of HIF-1α has been demonstrated in many common human cancers.

The flavone suppressed hypoxia-mediated nuclear HIF-1α expression. Under oxygen-poor conditions or hypoxia, P276-00 did not exhibit more cytotoxic activity in prostate cancer cells but arrested them. The tubular formation of human umbilical vein endothelial cells and migration of prostate cancer cells were also inhibited by P276-00 in vitro.

The researchers say that since it is non-toxic, has antitumor activity and the potential to inhibit the HIF-1 pathway, P276-00 should be considered as antiangiogenic chemotherapy for prostate cancer.


References

  1. Manohar, S. M. et al. Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1α and induces G2/M arrest under hypoxia in prostate cancer cells. Prostate Cancer P. D. 15, 15-27 (2012)